Search

Anticancer peptides (ACPs) are short protein sequences; they perform functions like some hormones and enzymes inside the body. The role of any protein or peptide is related to its structure and the sequence of amino acids that make up it. There are 20 types of amino acids in humans, and each of them has a particular characteristic according to its chemical structure. Current machine and deep learning models have been used to classify ACPs problems. However, these models have neglected Amino Acid Repeats (AARs) that play an essential role in the function and structure of peptides. Therefore, in this paper, ACPs offer a promising route for novel anticancer peptides by extracting AARs based on N-Grams and k-mers using two peptides' datasets. These datasets pointed to breast and lung cancer cells assembled and curated manually from the Cancer Peptide and Protein Database (CancerPPD). Every dataset consists of a sequence of peptides and their synthesis and anticancer activity on breast and lung cancer cell lines. Five different feature selection methods were used in this paper to improve classification performance and reduce the experimental costs. After that, ACPs were classified using four classifiers, namely AdaBoost, Random Forest Tree (RFT), Multi-class Support Vector Machine (SVM), and Multi-Layer Perceptron (MLP). These classifiers were evaluated by applying five well-known evaluation metrics. Experimental results showed that the breast and lung ACPs classification process provided an accurate performance that reached 89.25% and 92.56%, respectively. In terms of AUC, it reached 95.35% and 96.92% for both breast and lung ACPs, respectively. The proposed classifiers performed competently somewhat equally in AUC, accuracy, precision, F-measures, and recall, except for Multi-class SVM-based feature selection, which showed superior performance. As a result, this paper significantly improved the predictive performance that can effectively distinguish ACPs as virtual inactive, experimental inactive, moderately active, and very active. [ABSTRACT FROM AUTHOR]

Anticancer peptides (ACPs) are a group of peptides that exhibit antineoplastic properties. The utilization of ACPs in cancer prevention can present a viable substitute for conventional cancer therapeutics, as they possess a higher degree of selectivity and safety. Recent scientific advancements generate an interest in peptide-based therapies which offer the advantage of efficiently treating intended cells without negatively impacting normal cells. However, as the number of peptide sequences continues to increase rapidly, developing a reliable and precise prediction model becomes a challenging task. In this work, our motivation is to advance an efficient model for categorizing anticancer peptides employing the consolidation of word embedding and deep learning models. First, Word2Vec, GloVe, FastText, One-Hot-Encoding approaches are evaluated as embedding techniques for the purpose of extracting peptide sequences. Then, the output of embedding models are fed into deep learning approaches CNN, LSTM, BiLSTM. To demonstrate the contribution of proposed framework, extensive experiments are carried on widely-used datasets in the literature, ACPs250 and independent. Experiment results show the usage of proposed model enhances classification accuracy when compared to the state-of-the-art studies. The proposed combination, FastText+BiLSTM, exhibits 92.50% of accuracy for ACPs250 dataset, and 96.15% of accuracy for the Independent dataset, thence determining new state-of-the-art. [ABSTRACT FROM AUTHOR]

In recent decades, bioactive peptides have been gaining recognition in various biomedical areas, such as intracellular drug delivery (cell-penetrating peptides, CPPs) or anti-infective action (antimicrobial peptides, AMPs), closely associated to their distinct mode of interaction with biological membranes. Exploiting the interaction of membrane-active peptides with diverse targets (healthy, tumoral, bacterial or parasitic cell membranes) is opening encouraging prospects for peptides in therapeutics. However, ordinary peptides formed by L-amino acids are easily decomposed by proteases in biological fluids. One way to sidestep this limitation is to use topoisomers, namely versions of the peptide made up of D-amino acids in either canonic (enantio) or inverted (retroenantio) sequence. Rearranging peptide sequences in this fashion provides a certain degree of native structure mimicry that, in appropriate contexts, may deliver desirable biological activity while avoiding protease degradation. In this review, we will focus on recent accounts of membrane-active topoisomeric peptides with therapeutic applications as CPP drug delivery vectors, or as antimicrobial and anticancer candidates. We will also discuss the most common modes of interaction of these peptides with their membrane targets. [ABSTRACT FROM AUTHOR]

Cancer is one of the most dangerous diseases in the world, killing millions of people every year. Drugs composed of anticancer peptides have been used to treat cancer with low side effects in recent years. Therefore, identifying anticancer peptides has become a focus of research. In this study, an improved anticancer peptide predictor named ACP-GBDT, based on gradient boosting decision tree (GBDT) and sequence information, is proposed. To encode the peptide sequences included in the anticancer peptide dataset, ACP-GBDT uses a merged-feature composed of AAIndex and SVMProt-188D. A GBDT is adopted to train the prediction model in ACP-GBDT. Independent testing and ten-fold crossvalidation show that ACP-GBDT can effectively distinguish anticancer peptides from non-anticancer ones. The comparison results of the benchmark dataset show that ACP-GBDT is simpler and more effective than other existing anticancer peptide prediction methods. [ABSTRACT FROM AUTHOR]

Cancer is a Toxic health concern worldwide, it happens when cellular modifications cause the irregular growth and division of human cells. Several traditional approaches such as therapies and wet laboratory-based methods have been applied to treat cancer cells. However, these methods are considered less effective due to their high cost and diverse side effects. According to recent advancements, peptide-based therapies have attracted the attention of scientists because of their high selectivity. Peptide therapy can efficiently treat the targeted cells, without affecting the normal cells. Due to the rapid increase of peptide sequences, an accurate prediction model has become a challenging task. Keeping the significance of anticancer peptides (ACPs) in cancer treatment, an intelligent and reliable prediction model is highly indispensable. In this paper, a FastText-based word embedding strategy has been employed to represent each peptide sample via a skip-gram model. After extracting the peptide embedding descriptors, the deep neural network (DNN) model was applied to accurately discriminate the ACPs. The optimized parameters of DNN achieved an accuracy of 96.94 %, 93.41 %, and 94.02 % using training, alternate, and independent samples, respectively. It was observed that our proposed cACP-DeepGram model outperformed and reported ~10 % highest prediction accuracy than existing predictors. It is suggested that the cACP-DeepGram model will be a reliable tool for scientists and might play a valuable role in academic research and drug discovery. The source code and the datasets are publicly available at https://github.com/shahidakbarcs/cACP-DeepGram. [ABSTRACT FROM AUTHOR]

In the modern technological era, Anti-cancer peptides (ACPs) have been considered a promising cancer treatment. It's critical to find new ACPs to ensure a better knowledge of their functioning processes and vaccine development. Thus, timely and efficient ACPs using a computational technique are highly needed because of the enormous peptide sequences generated in the post-genomic era. Recently, numerous adaptive statistical algorithms have been developed for separating ACPs and NACPs. Despite great advancements, existing approaches still have insufficient feature descriptors and learning methods, limiting predictive performance. To address this, a trustworthy framework is developed for the precise identification of ACPs. Particularly, the presented approach incorporates four hypothetical feature encoding mechanisms namely: amino acid, dipeptide, tripeptide, and an improved version of pseudo amino acid composition are applied to indicate the motif of the target class. Moreover, principal component analysis (PCA) is employed for feature pruning, while selecting optimal, deep, and highly variated features. Due to the diverse nature of learning, experiments are performed over numerous algorithms to select the optimum operating method. After investigating the empirical outcomes, the support vector machine with hybrid feature space shows better performance. The proposed framework achieved an accuracy of 97.09% and 98.25% over the benchmark and independent datasets, respectively. The comparative analysis demonstrates that our proposed model outperforms as compared to the existing methods and is beneficial in drug development, and oncology. [ABSTRACT FROM AUTHOR]

World widely, cancer is considered a fatal disease and remains the major cause of death. Conventional medication approaches using therapies and anticancer drugs are deemed ineffective due to its high cost and harmful impacts on the normal cells. However, the innovation of anticancer peptides (ACPs) provides an effective way how to deals with cancer affected cells. Due to the rapid increases in peptide sequences, truly characterization of ACPs has become a challenging task for investigators. In this paper, an effort has been carried out to develop a reliable and intelligent computational method for the accurate discrimination of anticancer peptides. Three statistical feature representation schemes namely: Quasi-sequence order (QSO), conjoint triad feature, and Geary autocorrelation descriptor are applied to express motif of the target class. In order to eradicate irrelevant and noisy features, while select salient, profound and high variated features, principal component analysis is employed. Furthermore, the diverse nature of learning algorithms is utilized in order to select the best operational engine for the proposed model. After examining the empirical outcomes, support vector machine obtained quite encouraging results in combination with QSO feature space. It has achieved an accuracy of 96.91% and 89.54% using the main dataset and alternative dataset, respectively. It is observed that our proposed model shows an outstanding improvement compared to literature methods. It is expected that the developed model may be played a useful role in research academia as well as proteomics and drug development. • Computational model is developed for prediction of anticancer peptides. • Quasi-sequence order, conjoint triad feature, and Geary autocorrelation descriptor are used as feature extraction scheme. • PCA is applied as feature selection scheme. • Various classification algorithms are utilized. • Proposed model achieved quite promising results. [ABSTRACT FROM AUTHOR]

As cancer remains one of the main threats of human life, developing efficient cancer treatments is urgent. Anticancer peptides, which could overcome the significant side effects and poor results of traditional cancer treatments, have become a new potential alternative these years. However, identifying anticancer peptides by experimental methods is time consuming and resource consuming, it is of great significance to develop effective computational tools to quickly and accurately identify potential anticancer peptides from amino acid sequences. For most current computational methods, feature representation plays a key role in their final successes. This study proposes a novel fast and accurate approach to identify anticancer peptides using diversified feature representations and ensemble learning method. For the feature representations, the information is encoded from multidimensional feature spaces, including sequence composition, sequence-order, physicochemical properties, etc. In order to better model the potential relationships of peptides, multiple ensemble classifiers, LightGBMs, are applied to detect the different feature sets at first. Then the obtained multiple outputs are used as inputs of the support vector machine classifier, which effectively identifies anticancer peptides. Experimental results on cross validation and independent test sets demonstrate that our method can achieve better or comparable performances compared with other state-of-the-art methods. [ABSTRACT FROM AUTHOR]

We generalize chaos game representation (CGR) to higher dimensional spaces while maintaining its bijection, keeping such method sufficiently representative and mathematically rigorous compare to previous attempts. We first state and prove the asymptotic property of CGR and our generalized chaos game representation (GCGR) method. The prediction follows that the dissimilarity of sequences which possess identical subsequences but distinct positions would be lowered exponentially by the length of the identical subsequence; this effect was taking place unbeknownst to researchers. By shining a spotlight on it now, we show the effect fundamentally supports (G)CGR as a similarity measure or feature extraction technique. We develop two feature extraction techniques: GCGR-Centroid and GCGR-Variance. We use the GCGR-Centroid to analyze the similarity between protein sequences by using the datasets 9 ND5, 24 TF and 50 beta-globin proteins. We obtain consistent results compared with previous studies which proves the significance thereof. Finally, by utilizing support vector machines, we train the anticancer peptide prediction model by using both GCGR-Centroid and GCGR-Variance, and achieve a significantly higher prediction performance by employing the 3 well-studied anticancer peptide datasets. [ABSTRACT FROM AUTHOR]

Cancer is one of the most dangerous threats to human health. One of the issues is drug resistance action, which leads to side effects after drug treatment. Numerous therapies have endeavored to relieve the drug resistance action. Recently, anticancer peptides could be a novel and promising anticancer candidate, which can inhibit tumor cell proliferation, migration, and suppress the formation of tumor blood vessels, with fewer side effects. However, it is costly, laborious and time consuming to identify anticancer peptides by biological experiments with a high throughput. Therefore, accurately identifying anti-cancer peptides becomes a key and indispensable step for anticancer peptides therapy. Although some existing computer methods have been developed to predict anticancer peptides, the accuracy still needs to be improved. Thus, in this study, we propose a deep learning-based model, called ACPNet, to distinguish anticancer peptides from non-anticancer peptides (non-ACPs). ACPNet employs three different types of peptide sequence information, peptide physicochemical properties and auto-encoding features linking the training process. ACPNet is a hybrid deep learning network, which fuses fully connected networks and recurrent neural networks. The comparison with other existing methods on ACPs82 datasets shows that ACPNet not only achieves the improvement of 1.2% Accuracy, 2.0% F1-score, and 7.2% Recall, but also gets balanced performance on the Matthews correlation coefficient. Meanwhile, ACPNet is verified on an independent dataset, with 20 proven anticancer peptides, and only one anticancer peptide is predicted as non-ACPs. The comparison and independent validation experiment indicate that ACPNet can accurately distinguish anticancer peptides from non-ACPs. [ABSTRACT FROM AUTHOR]

Recently, anticancer peptides (ACPs) have emerged as unique and promising therapeutic agents for cancer treatment compared with antibody and small molecule drugs. In addition to experimental methods of ACPs discovery, it is also necessary to develop accurate machine learning models for ACP prediction. In this study, features were extracted from the three-dimensional (3D) structure of peptides to develop the model, compared to most of the previous computational models, which are based on sequence information. In order to develop ACPs with more potency, more selectivity and less toxicity, the model for predicting ACPs, hemolytic peptides and toxic peptides were established by peptides 3D structure separately. Multiple datasets were collected according to whether the peptide sequence was chemically modified. After feature extraction and screening, diverse algorithms were used to build the model. Twelve models with excellent performance (Acc > 90%) in the ACPs mixed datasets were used to form a hybrid model to predict the candidate ACPs, and then the optimal model of hemolytic peptides (Acc = 73.68%) and toxic peptides (Acc = 85.5%) was used for safety prediction. Novel ACPs were found by using those models, and five peptides were randomly selected to determine their anticancer activity and toxic side effects in vitro experiments. [ABSTRACT FROM AUTHOR]